CA Patent

CA2876737A1 — Polymorphic forms of rifaximin

Assigned to Apotex Pharmachem Inc · Expires 2013-12-19 · 12y expired

What this patent protects

Provided for in the instant application are two additional forms of rifaximin, namely rifaximin polymorphic forms ???-III and APO-IV. Also provided are allegedly novel processes for preparing the previously disclosed rifaximin polymorphic forms APO-I and ???-II. Rifaximin is a no…

USPTO Abstract

Provided for in the instant application are two additional forms of rifaximin, namely rifaximin polymorphic forms ???-III and APO-IV. Also provided are allegedly novel processes for preparing the previously disclosed rifaximin polymorphic forms APO-I and ???-II. Rifaximin is a non-aminoglycoside antibiotic that has previously been found to be useful for the treatment of traveller's diarrhea caused by Escherichia coli bacteria, as well as in the treatment of irritable bowel syndrome, diverticular disease, hepatic encephalopathy, pyogenic skin infections and as an antibacterial prophylactic prior to colon surgery.

Drugs covered by this patent

Patent Metadata

Patent number
CA2876737A1
Jurisdiction
CA
Classification
—
Expires
2013-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Apotex Pharmachem Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.